Abstract
The existing clinical trials database for lamotrigine favors its utility in preventing (mainly depressive) recurrences in bipolar I disorder. It may best be viewed as a mood stabilizing agent with predominantly antidepressant properties—particularly as prophylaxis—with a therapeutic benefit that is less well-established either acutely or in patients with conditions other than bipolar I disorder. Design limitations of existing trials limit the extent to which its possible broader pharmacodynamic properties can be generalized or brought to bear as an evidence-based option in wider clinical populations with mood dysregulation.
| Original language | English |
|---|---|
| Article number | 23ac15219 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 85 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2024 |
Fingerprint
Dive into the research topics of 'Where Does Lamotrigine Fit in the Pharmacotherapy of Mood Disorders? An Evidence-Based Appraisal'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver